PHARMACOLOGICAL EFFECT OF POLYSORBATE 80 IN CANCER CHEMOTHERAPY
Objective- Tween 80 (Polysorbate 80) is a classical non-ionic surface-active detergent. It is widely used as an additive in pharmaceuticals and in the food industry.Â Many of the Tweens are considered to be carcinogens. Here in this study an attempt was made to find out whether the tween 80Â used as an excipient in an anti cancer drug, Methotrexate affected its therapuetic efficiency or not.
Method- Hepatocellularcarcinogenesis (HCC) was induced in the wister rats by the administration of a single dose chemical carcinogen DENA (150 mg/kg i. p.). The animals exposed to DENA were treated with pure Methotrexate (MTX) and marketed MTX (0.14mg/kg by oral route through force feeding) and Tween 80 (0.14mg/kg by p. o.).
Result- Exposure of DENA and Tween 80 elevated the levels of SGOT, SGPT, ALP, and AFP in Wistar rats. Histopathological examinations of the liver tissue showed marked carcinogenicity of the chemical carcinogen and excipients, while pure MTX treated group showed normal liver cell architecture.
Conclusion- The study revealed that the excipient polysorbate 80 used in the marketed formulation of Methotrexate decreased the efficacy of theÂ pure drug (pure Methotrexate).
Keywords: Polysorbate80 , Excipient, Efficacy, Diethylnitrosamine(DENA), Hepatocarcinogenesis, Methotrexate (MTX).
2. Tije AJ, Verweij J, Loos WJ, Sparreboom A. Pharmacological effects of formulation vehicles: implications for cancer chemotherapy. Clin Pharmacokinet 2003;42:665âˆ’85.
3. Limaye S, Steele RH, Quin J, Cleland B. An allergic reaction to erythropoietin secondary to polysorbate hypersensitivity. J Allergy Clin Immunol 2002; 110(3):530.
4. Coors EA, Seybold H, Merk HF, Mahler V. Polysorbate 80 in medical products and nonimmunologic anaphylactoid reactions. Ann Allergy Asthma Immunol. 2005;95(6):593-9.
5. GajdovÃ¡ M, Jakubovsky J, VÃ¡lky J. Delayed effects of neonatal exposure to Tween 80 on female reproductive organs in rats. Food Chem Toxicol 1993; 31(3):183-90.
6. Barnett JB. Immunosuppressive effects of tween 80 on mice. Int Arch Allergy Appl Immunol 1981;66(2):229-32.
7. Kitazawa S, Ishizu M, Kimura K. Effect of surfactants on transmucosal fluid movement and drug absorption from rat small intestine. Chem Pharm Bull (Tokyo) 1977;25(4):590-600.
8. Azmin MN, Stuart JF, Calman KC, Florence AT. Effects of polysorbate 80 on the absorption and distribution of oral methotrexate (MTX) in mice. Cancer Chemother Pharmacol 1982;9(3):161-4.
9. Badiu I, Geuna M, Heffler E, Rolla G. Hypersensitivity reaction to human papillomavirus vaccine due to polysorbate 80. BMJ Case Rep 2012;8.
10. Varma RK, Kaushal R, Junnarkar AY, Thomas GP, Naidu MU, Singh PP, et al. Polysorbate 80: a pharmacological study. Arzneimittelforsch 1985;35(5):804-8.
11. Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. Lancet 1995;345(8960):1312-3.
12. Al-Hallak MH, Azarmi S, Sun C, Lai P, Prenner EJ, Roa WH, et al. Pulmonary toxicity of polysorbate-80-coated inhalable nanoparticles; in vitro and in vivo evaluation. AAPS J 2010;12(3):294-9.
13. Peeters BW, Cheung KS, Vossen JM, Coenen AM. Some solvents for antiepileptics have proepileptic potencies in the WAG/Rij rat model for absence epilepsy. Brain Res Bull 1992;29(3-4):515-7.
14. Larry RS, Ginny LK. The synergistic effect of polysorbate 80 upon the toxicity of tri-n-butyltin chloride. Appl Organomet Chem 1990;4(4):379â€“81.
15. Pesce AJ, McKean DL. Toxic susceptibilities in the newborn with special consideration of polysorbate toxicity. Ann Clin Lab Sci 1989;19(1):70-3.
16. Steele RH, Limaye S, Cleland B, Chow J, Suranyi MG. Hypersensitivity reactions to the polysorbate contained in recombinant erythropoietin and darbepoietin. Nephrology (Carlton) 2005;10(3):317-20.
17. Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterol 2004;127:S5-S16.
18. Braun J, Rau R. An update on methotrexate. Curr Opin Rheumatol 2009;21:216-23.
19. Coleman WB. Mechanisms of human hepatocarcinogenesis. Curr Mol Med 2003;3(6):573-88.
20. Dickson ER, Grambsch PM, Fleming TR, Fisher LD, Langworthy A. Prognosis in primary biliary cirrhosis: model for decision making. Hepatology 1989;10:1-7.
21. Tessitore L, Tomasi C, Greco M, Sesca E, Laconi E, Maccioni O, et al. A subnecrogenic dose of diethylnitrosamine is able to initiate hepatocarcinogenesis in the rat when coupled with fasting/refeeding. Carcinog 1996;17(2):289-92.
22. Thirunavukkarasu C, Sakthisekaran D. Sodium selenite modulates tumour marker indices in N-nitrosodiethylamine initiated and phenobarbital-promoted rat liver carcinogenesis. Cell Bio Funct 2003;21:147-53.
23. Patel PS, Rawal GN, Bala DB. Combined use of serum enzyme levels as tumour markers in cervical carcinoma patients. Tumor Biol 1994;15:45-51.
24. Kaplovitz N, Tsukamoto H. Oxidative stress and liver disease. Prog Liver Dis 1996;14:131.
25. Kobayashi T, Kawakubo T. Prospective investigation of tumour markers and risk assessment in early cancer screening. Cancer 1994;73:1946-53.
26. Trevisani F, DiIntino PE, Morselli L. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol 2001;34:570-5.
27. McIntyre N, Rosalki S. Biochemical Investigation in the Management of Liver Disease. In: Hepatobiliary Diseases. Springer-Verlag Berlin 1992;39-71.
28. Rosalki SB, Mcintyre N. Biochemical investigations in the management of liver disease. Oxford textbook of clinical hepatology 1999;2:503-21.
29. Yeo W, Mo FK, Koh J, Chan AT, Leung T, Hui P, et al. Quality of life is predictive of survival in patients with unresectable hepatocellular carcinoma. Ann Oncol 2006;17:1083-9.